针对长非编码RNA作为抗EGFR耐药机制的新调节剂
Mostafa Akbarzadeh-Khiavi1,2, Azam Safary3, Yadollah Omidi4
1Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
BioImpacts : BI
|February 8, 2024
概括
长非编码RNAs (lncRNAs) 可能在结直肠癌 (CRC) 中克服对表皮生长因子受体 (EGFR) 治疗的耐药性. 针对 lncRNAs 与当前治疗一起,可以改善各种固体瘤的结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 表皮生长因子受体 (EGFR) 的过度表达驱动着结直肠癌 (CRC) 的进展.
- 抗EGFR疗法至关重要,但面临着重大的耐药性挑战.
- 了解耐药机制是提高癌症治疗疗效的关键.
研究的目的:
- 研究长非编码RNAs (lncRNAs) 在CRC中抗EGFR治疗耐药性的作用.
- 探索 lncRNAs 作为克服治疗耐药性的潜在目标.
- 为开发新型抗EGFR疗法提供见解.
主要方法:
- 对癌症中 lncRNAs 和 EGFR 信号传导的当前研究的综述.
- 分析新出现的证据,将lncRNA与抗EGFR耐药机制联系起来.
- 探索涉及 lncRNA 向的潜在治疗策略.
主要成果:
- 新出现的证据表明,lncRNAs在调节抗EGFR疗法的耐药性方面发挥着作用.
- lncRNAs与CRC治疗失败背后的复杂机制有关.
- lncRNA失调有助于EGFR驱动的癌症中不受控制的细胞生长.
结论:
- lncRNAs是结直肠癌中抗EGFR治疗耐药性的潜在调节者.
- 针对 lncRNAs 与现有疗法结合使用可能改善临床结果.
- 对lncRNA参与的进一步研究可以指导针对固体瘤的新型抗EGFR策略的开发.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
相关概念视频
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
